Sunday, April 15, 2012

Neupro Approved by U.S. FDA for Parkinson's Disease and Restless Legs Syndrome

 We know that, Rotigotine (see below structure, Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.

 
Neupro Approved by U.S. FDA for Parkinson's Disease and Restless Legs Syndrome:  UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic...

Saturday, April 14, 2012

Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia

 In continuation of my update on Liraglutide

Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia:  Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) to update the product label for Victoza (liraglutide [rDNA origin] injection) to include data showing superior blood...

Friday, April 13, 2012

Weight loss pill Qnexa wins panel vote and awaits approval

We know that, The combination of the drugs phentermine (see structure-1) and topiramate (structure -2) (trade name Qnexa) is an investigational medication for the treatment ofobesity and related conditions such as type 2 diabetes and has been found to lower blood pressure and cholesterol.  Qnexa is being developed by Vivus, a California pharmaceutical company.  Phentermine is an appetite suppressant and stimulant of the amphetamine andphenethylamine class. Topiramate is an anticonvulsant that has weight loss side effects.

Structure 1
Structure-2
       
Weight loss pill Qnexa wins panel vote and awaits approval: The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.
                                                                                                                       

Thursday, April 12, 2012

Sucampo announces positive results from lubiprostone phase 3 trial on OBD

We know that, Lubiprostone (rINN, marketed under the trade name Amitiza) is a medication used in the management of chronic idiopathicconstipation and irritable bowel syndrome. It was approved by the U.S. Food and Drug Administration (FDA) for this purpose on 31 January 2006.

Sucampo announces positive results from lubiprostone phase 3 trial on OBD: Sucampo Pharmaceuticals, Inc. today announced positive top-line results from an open-label phase 3 clinical trial designed to evaluate the long-term safety and efficacy of lubiprostone in opioid-induced bowel dysfunction (OBD) patients with chronic, non-cancer-related pain.

Wednesday, April 11, 2012

Metformin may protect against liver cancer

In continuation of my update on Metformin

Metformin may protect against liver cancer: Metformin, a widely used, well-tolerated drug prescribed for patients with diabetes, may protect against liver cancer, according to a new study.

Tuesday, April 10, 2012

Potential Method to Control Obesity: Red Wine, Fruit Compound Could Help Block Fat Cell Formation

A compound found in red wine, grapes and other fruits, and similar in structure to resveratrol, is able to block cellular processes that allow fat cells to develop, opening a door to a potential method to control obesity, according to a Purdue University study. 

While similar in structure to resveratrol -- the compound found in red wine, grapes and peanuts that is thought to combat cancer, heart disease and neurodegenerative diseases -- piceatannol might be an important weapon against obesity. Resveratrol is converted to piceatannol in humans after consumption.

"Piceatannol (see structure) actually alters the timing of gene expressions, gene functions and insulin action during adipogenesis, the process in which early stage fat cells become mature fat cells," Kim said. "In the presence of piceatannol, you can see delay or complete inhibition of adipogenesis."

Ref : http://www.jbc.org/content/287/14/11566.abstract?sid=709d2cb0-7757-468e-9a5b-4160072e5e24 

Monday, April 9, 2012

Antipsychotic drug, Olanzapine, may be helpful treatment for anorexia nervosa


In continuation of my update on Olanzapine..

Low doses of a commonly used atypical antipsychotic drug improved survival in a mouse model of anorexia nervosa, University of Chicago researchers report this month. The result offers promise for a common and occasionally fatal eating disorder that currently lacks approved drugs for treatment.

Antipsychotic drug may be helpful treatment for anorexia nervosa

Sunday, April 8, 2012

Use of common pesticide, imidacloprid, linked to bee colony collapse

We know that, Imidacloprid is a systemic insecticide which acts as an insect neurotoxin and belongs to a class of chemicals called the neonicotinoids which act on the central nervous system of insects with much lower toxicity to mammals. The chemical works by interfering with the transmission of stimuli in the insect nervous system. Specifically, it causes a blockage in a type of neuronal pathway (nicotinergic) that is abundant in insects and not in warm-blooded animals (making the chemical selectively toxic to insects and not warm-blooded animals). This blockage leads to the accumulation of acetylcholine, an important insect neurotransmitter, resulting in the insect's paralysis, and eventually death. It is effective on contact and via stomach action

Use of common pesticide, imidacloprid, linked to bee colony collapse: The likely culprit in sharp worldwide declines in honeybee colonies since 2006 is imidacloprid, one of the most widely used pesticides, according to a new study.

Saturday, April 7, 2012

Immunotherapy and Chemotherapy Regimen May Prolong Survival in Advanced Cancers

In continuation of my update on interleukin and retinoic acid

Cancer patients who receive a combination of low-dose interleukin-2 and retinoic acid after conventional therapy seem to live longer than those who don't get the combination. 


Retinoic acid is derived from vitamin A. Interleukin-2, a compound that fortifies the immune system, is approved at high doses to treat "metastatic" melanoma and kidney cancer. Metastatic means that a cancer has spread.
The study showed that "these biological compounds may work at low doses. Bigger doses are not always better," said lead author Dr. Francesco Recchia, director of the oncology department at Civilian Hospital in Avezzano, Italy.
Recchia stumbled upon the possibility of using low-dose interleukin-2 (IL-2) when he switched a patient with metastatic melanoma who didn't tolerate high doses to a lower dose, and the patient had an extended response to the therapy.
This study involved 500 patients who had already responded well to chemotherapy. They had a variety of cancers, including ovarian, lung, colon, stomach, kidney, melanoma, breast and pancreatic.

Friday, April 6, 2012

Berries, Tea May Cut Men's Odds for Parkinson's: Study


In continuation of my update on the benefits of   berries, apple, tea...

Berries, Tea May Cut Men's Odds for Parkinson's: Study:  - Regularly consumption of food and drink rich in substances called flavonoids, such as berries, apples, tea and red wine, can lower a man's risk of developing Parkinson's disease by 40 percent, new research suggests.